Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence
Open Access
- 5 August 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (11), 2376-2384
- https://doi.org/10.1093/ndt/gfi025
Abstract
Background. While it is recommended that H2 receptor antagonists (H2RAs) be dose reduced in the presence of low glomerular filtration rate (GFR), in practice such adjustments often do not occur. We reviewed the evidence for this recommendation. Methods. We searched multiple medical reference databases for relevant cohort studies and randomized clinical trials. Studies that enrolled five or more participants with low GFR who also received at least one unadjusted dose of an H2RA, and who were compared with controls were included. Data were abstracted on study and participant characteristics and drug-related adverse effects. Pharmacokinetic measures were pooled using meta-analysis. Results. A total of 22 articles were included, comprising 19 unique cohort studies. With declining GFR, there was a significant increase in the area under the curve (AUC) and elimination half-life (t1/2) of the serum drug concentration of H2RAs (P80 ml/min/1.73 m2, drug AUC increased by 200% when the GFR was 30 ml/min/1.73 m2, and by 300% when the GFR was 20 ml/min/1.73 m2. In hospitalized patients with low GFR, reducing the interval dose of intravenous H2RA was associated with fewer adverse reactions. The gastro-protective effects of H2RAs were similar with reduced and unadjusted doses. Conclusions. Reducing the dose of H2RAs in persons with low GFR will decrease drug expenditure and may prevent adverse events, without a change in efficacy. Quality assurance programmes, which improve deficiencies in H2RAs prescribing, appear justified.Keywords
This publication has 43 references indexed in Scilit:
- Prescriptions for antiulcer drugs in Australia: volume, trends, and costsBMJ, 2001
- The Use of Intravenous H2-Receptor Antagonists in A Tertiary Care HospitalThe American Journal of Gastroenterology, 1999
- A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical VentilationNew England Journal of Medicine, 1998
- Famotidine for the Prevention of Gastric and Duodenal Ulcers Caused by Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1996
- Clinical Pharmacokinetics of FamotidineClinical Pharmacokinetics, 1991
- Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor AntagonistsClinical Pharmacokinetics, 1991
- Newer H2-Receptor AntagonistsClinical Pharmacokinetics, 1988
- Cimetidine Use in Nursing Homes: Prolonged Therapy and Excessive DosesJournal of the American Geriatrics Society, 1987
- Clinical Pharmacology of Famotidine: A SummaryJournal of Clinical Gastroenterology, 1987
- Clinical Pharmacokinetics of RanitidineClinical Pharmacokinetics, 1984